Daniel Soteres, MD
Allergy · Colorado Springs, CONPI 1679573588
Payments from drug & device makers
Across 2,146 payments — averaging $2339.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.5M
- Takeda Pharmaceuticals U.S.A., Inc.$695K
- AstraZeneca$677K
- Teva Pharmaceuticals USA, Inc.$377K
- Biocryst Pharmaceuticals, Inc.$189K
- Sanofi US Services Inc.$179K
- plus $1.4M from 39 others
Across 1 payment — averaging $29.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$30
What the payments were for
- Consulting fees$230,79336%
- Speaking & faculty fees$343,83353%
- Travel & lodging$43,4087%
- Food & beverage$31,8755%
- Education$1250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orladeyo$96,464
- TAKHZYRO$92,565
- DUPIXENT$86,936
- RUCONEST$80,835
- CINRYZE$68,309
- AIRSUPRA$32,408
- Haegarda$16,296
- DAWNZERA$12,718
- XOLAIR$11,776
- Andembry$11,059
- PALFORZIA$8,690
- CINQAIR$3,779
- Xhance$3,051
- ProAir Digihaler$1,680
- AirDuo RespiClick$1,680
- ArmonAir Digihaler$1,680
- Nityr$1,672
- EUCRISA$1,480
- Rhapsido$1,075
- CUTAQUIG$750
How this compares
Too few allergy providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 38 | $1,576,186 |
| OrladeyoBerotralstat Hydrochloride | 12 | $558,215 |
| IcatibantIcatibant Acetate | 14 | $182,202 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 22 | $58,079 |
| XolairOmalizumab | 21 | $41,168 |
| NucalaMepolizumab | 11 | $40,689 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $36,355 |
| Spiriva RespimatTiotropium Bromide | 17 | $17,865 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $17,730 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $9,306 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $4,558 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,313 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $2,962 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,511 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $695,006 | $1,576,18638 claims |
| Biocryst US Sales Co., LLCOrladeyo | $85,380 | $558,21512 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,144 | $89,66378 claims |
| CSL BehringPrivigen | $59,491 | $58,07922 claims |
| Genentech, Inc.Xolair | $128,125 | $41,16821 claims |
| Boehringer IngelheimSpiriva Respimat | $134 | $17,86517 claims |
| AstraZenecaSymbicort | $676,657 | $17,73048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other allergy in Colorado Springs
- Nathanael BradyColorado Springs$974K
- Christianne McGrathColorado Springs$11K
- Mark BoguniewiczDenver$1.1M
- Regan PyleAvon$72K
- William LantingFort Collins$36K
- Carmen LaronnCentennial$844
- William SilversCentennial$160
- Mark MenichBoulder$132
- Karen AndrewsBoulder$132
- Kirstin CarelAurora$36
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.